- March 15, 2022
- Newsletter
- 617-430-5616
Menu
ADVERTISEMENT
ADVERTISEMENT
Brand Name :
Sustiva
Synonyms :
efavirenz
Class :
Antiviral agents and Anti-HIV (antiretroviral)
No drug interaction found for efavirenz and .
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
may increase the serum concentration of CYP3A4 substrates
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may enhance the serum concentrations of active metabolites
may diminish the serum concentration
may diminish the serum concentration
budesonide and formoterol (inhalation)
may enhance the serum concentration of CYP3A4 inhibitor
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the serum concentration when combined with CYP3A4 Inducers (Strong)
may increase or decrease the activity of this enzyme when combined with sparsentan
may diminish the serum concentration when combined with alfentanil
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with aripiprazole
may diminish the serum concentration when combined with atogepant
may diminish the serum concentration when combined with belumosudil
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with fenfluramine
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
brexpiprazole : they may diminish the serum concentration of CYP3A4 Inducers
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
clarithromycin: they may enhance serum concentrations of CYP3A4 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
dexamethasone: they may diminish the serum concentration of CYP3A4 Inducers
diltiazem: they may diminish the serum concentration of CYP3A4 Inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
CYP3A4 inducers: they may diminish the serum concentration of eravacycline
erlotinib: they may diminish the serum concentration of CYP3A4 inducers
exemestane: they may diminish the serum concentration of CYP3A4 Inducers
felodipine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 inducers: they may diminish the serum concentration of ganaxolone
may diminish the serum concentration of zanubrutnib
drospirenone/ethinyl estradiol/levomefolate
may diminish the serum concentration of Hormonal Contraceptives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
It may diminish the effect when combined with pemigatinib by affecting CYP3A4 metabolism
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
QTc interval increases on taking efavirenz and lenvatinib together. Avoid or take an alternate drug
the effect of efavirenz is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
efavirenz decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased QTC interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of efavirenz
efavirenz decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
it will decrease the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
relugolix/estradiol/norethindrone
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of OCT1 substrates in the serum
may diminish the serum concentration
may diminish the serum concentration
may enhance the serum concentration
they decrease the concentration of rilpivirine
may decrease the serum concentration of macimorelin
may enhance the serum concentration
may decrease the serum concentration of lenacapavir
may enhance the serum concentration
they decrease the concentration of buprenorphine in the serum
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
they decrease the concentration of glasdegib in the serum
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
may enhance the serum concentration of elbasvir/grazoprevir
may decrease the serum concentration of elbasvir/grazoprevir
it increases the concentration of CYP3A4 substrates in the serum
It may enhance QTc interval when combined with pentamidine
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of capmatinib
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
they decrease the concentration of lurbinectedin in the serum
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
may reduce the level of serum concentration of estrogen drugs
bazedoxifene/conjugated estrogens
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
May decrease the serum concentration
May decrease the serum concentration
May decrease the serum concentration
May decrease the serum concentration
May decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
bazedoxifene/conjugated estrogens
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both the drugs are combined, the metabolism of carmustine decreases
interaction with trimetrexate may increase liver toxicity, induce vomiting and abdominal pain
has a synergistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may reduce therapeutic effects of docetaxel
encorafenib increases the toxicity of efavirenz and decreases its effectiveness by altering intestinal/hepatic CYP3A4 enzyme metabolism
efavirenz decreases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the levels of serum concentration of clozapine
may increase the levels of serum concentrations of clobazam
hydrocodone/chlorpheniramine/pseudoephedrine
may diminish the serum concentration
it increases the concentration of OCT1 substrates in the serum
may increase the serum concentration
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of erdafitinib
may decrease the serum concentration of erdafitinib.
it decreases the concentration of antiretroviral agent in the serum
azelastine/fluticasone intranasal
may enhance the serum concentration
may decrease the serum concentration of macitentan
may decrease the level of serum concentration of pretomanid
may decrease the serum concentration of CYP2C9 substrates
CYP3A4 Inducers may decrease the serum concentration of eliglustat
may decrease the serum concentration of encorafenib
may decrease the serum concentration of estazolam
may decrease the serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may increase the serum concentration of abemaciclib
may diminish the serum concentration of corticosteroids
may enhance the serum concentration of CYP2C19 Inhibitors
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the level of serum concentrations of itraconazole
CYP3A4 inhibitors increase the concentration of carbamazepine in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
may diminish the serum concentration when combined with selpercatinib
may diminish the serum concentration when combined with upadacitinib
may enhance the serum concentration of flibanserin
may increase the serum concentration of active metabolites
CYP3A4 inhibitors increase the concentration of rivaroxaban
may reduce the levels of serum concentration of tivozanib
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration of Sulfonylureas
may increase the serum concentration of Lidocaine
may diminish the serum concentration of lidocaine
may increase the levels of serum concentration of pimavanserin
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined
eszopiclone: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
hydrocodone: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
meperidine: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the serum concentration of Buprenorphine
estrogens esterified/methyltestosterone
may increase the thrombogenic effect of androgens
estrogens esterified/methyltestosterone
may diminish the serum concentration when combined
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
it decreases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the concentration of hormonal contraceptives in serum
they increase the concentration of glasdegib in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
Dosage Forms & Strengths
Tablet, Oral:
50 mg
200 mg
Capsule, Oral:
600 mg
600
mg
Orally
once a day
in combination with tenofovir and lamivudine
Discontinue therapy immediately, if moderate to severe hepatic impairment is noticed
Note: Not recommended to use in combination with abacavir and lamivudine, especially for patients receiving pre-antiretroviral therapy
Dosage Forms & Strengths
Tablet, Oral:
50 mg
200 mg
Capsule, Oral:
600 mg
Note: Not recommended to use in combination with abacavir and lamivudine, especially for patients receiving pre-antiretroviral therapy
Not recommended for <3 months infants
Oral Dose instructions based on weight:
10 kg to <15 kg: 200 mg/day orally
15 kg to <20 kg: 250 mg/day orally
20 kg to <25 kg: 300 mg/day orally
25 kg to 32.5 kg: 350 mg/day orally
32.5 to <40 kg: 400 mg/day orally
>40 kg: 600 mg/day orally
Discontinue therapy immediately, if moderate to severe hepatic impairment noticed
Refer to adult dosing
Frequency defined:
>10%
Skin rash
Increased serum cholesterol
1% to 10%:
Angina pectoris
Facial edema
Atrial fibrillation
Myocardial infarction
Syncope
Peripheral neuropathy
Abnormal dreams
Anxiety
Confusion
Drowsiness
Disorientation
Disturbance in attention
Nervousness
Hypoesthesia
Prurigo
Night sweats
Xeroderma
Diabetes
lipohypertrophy
pancreatitis
stomatitis
anorexia
constipation
flatulence
gastritis
Post-marketing:
Angioedema
Erythema multiforme
Hemorrhagic stroke
Rhabdomyolysis
Stevens-Johnson syndrome
Dress syndrome
Pregnancy consideration: Efavirenz can moderately transfer across the human placenta.
Lactation: efavirenz can be excreted in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: Efavirenz
Pronunciation: efavirenz
Why do we use Efavirenz?
It is used to treat viral infections such as HIV-1 infection.
ADVERTISEMENT
Brand Name :
Sustiva
Synonyms :
efavirenz
Class :
Antiviral agents and Anti-HIV (antiretroviral)
Dosage Forms & Strengths
Tablet, Oral:
50 mg
200 mg
Capsule, Oral:
600 mg
600
mg
Orally
once a day
in combination with tenofovir and lamivudine
Discontinue therapy immediately, if moderate to severe hepatic impairment is noticed
Note: Not recommended to use in combination with abacavir and lamivudine, especially for patients receiving pre-antiretroviral therapy
Dosage Forms & Strengths
Tablet, Oral:
50 mg
200 mg
Capsule, Oral:
600 mg
Note: Not recommended to use in combination with abacavir and lamivudine, especially for patients receiving pre-antiretroviral therapy
Not recommended for <3 months infants
Oral Dose instructions based on weight:
10 kg to <15 kg: 200 mg/day orally
15 kg to <20 kg: 250 mg/day orally
20 kg to <25 kg: 300 mg/day orally
25 kg to 32.5 kg: 350 mg/day orally
32.5 to <40 kg: 400 mg/day orally
>40 kg: 600 mg/day orally
Discontinue therapy immediately, if moderate to severe hepatic impairment noticed
Refer to adult dosing